Barclays Reiterates Buy Rating on Natera with $260 Target
Barclays maintains its positive outlook on Natera, Inc. with a reiterated buy rating and a $260 price target, a 0.73% downside from the current price.
Key Points
- Barclays reiterated its buy rating on Natera, Inc. (NTRA) with a $260 price target on June 24, 2026.
- Barclays's $260 price target implies 0.73% downside from Natera, Inc.'s ($NTRA) current $261.91 share price.
- Natera shares traded at $247.66 on Wednesday, with a market cap of $32.77 billion and a 52-week high of $256.36.
- Insiders at Natera, including Executive Chairman Matthew Rabinowitz, sold shares in planned transactions in June 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 24, 2026, Barclays reiterated its buy rating for Natera, Inc. (NasdaqGS: NTRA), setting a price target of $260. Analyst Luke Sergott maintained the positive outlook, signaling continued confidence in the company's prospects.
Barclays vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Natera, Inc. Stock Down 19.7%
Shares of Natera traded near $247.66 on Wednesday. The company, which operates in the healthcare sector focusing on diagnostics and research, boasts a market cap of approximately $32.77 billion. Despite not having a meaningful P/E ratio due to its unprofitability, Natera shows a beta of 1.544, indicating some volatility compared to the market. The stock's 52-week range spans from $131.81 to $256.36, with moving averages of $207.88 for 50 days and $206.57 for 200 days.
$NTRA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Natera reported revenues of about $2.5 billion, with a growth rate of 38.8%. However, the company has a net margin of -9% and a return on equity of -15%, reflecting ongoing challenges in achieving profitability. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Natera, Inc.
Recently, several insiders at Natera have been selling shares. Executive Chairman Matthew Rabinowitz executed planned sales of 50,000 shares on both June 15 and June 12, 2026, at average prices of $214.91 and $214.03, respectively. Other insiders, including Sheena Jonathan and Gail Boxer Marcus, also sold shares in June.
Analysts Set New Price Targets
On June 24, 2026, Barclays maintained its buy rating with a $260 price target for Natera. Other analysts have also shown confidence in the stock. BTIG reiterated a buy rating with a $270 target on June 23, while RBC Capital reinstated its buy rating with a $275 target on June 12. Goldman Sachs began coverage with a hold rating and a $245 target on June 5. The consensus among 20 analysts remains a buy, with an average target price of $260.05.
About Natera, Inc.
Natera, Inc. is a diagnostics company headquartered in Austin, Texas. It develops and sells molecular testing services worldwide, including its flagship product Signatera, a personalized ctDNA blood test for monitoring cancer recurrence and treatment response. The company also offers a range of other tests for prenatal screening, hereditary cancer, and organ transplant rejection. Led by CEO Steven Leonard Chapman, Natera employs over 6,000 people.
Bottom Line
Barclays' reiteration of its buy rating for Natera, Inc. highlights enduring confidence in the company's market position and growth potential. Investors continue to monitor Natera's performance closely, especially given its significant presence in the diagnostics and research sector. As always, keep in mind that analyst ratings are based on past data and do not necessarily predict future performance.
Get Natera, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NTRA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.